(Q72776916)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7949207%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

review article

1 reference

title

Second generation aromatase inhibitor--4-hydroxyandrostenedione (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7949207%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

author name string

M Dowsett

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7949207%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

R C Coombes

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7949207%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

publication date

1 January 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7949207%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

29 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7949207%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7949207%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7949207%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

page(s)

81-87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7949207%20AND%20SRC:MED&resulttype=core&format=json

Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.

29 October 2019

cites work

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men

1 reference

12 December 2020

An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients

1 reference

12 December 2020

Determination of 4-hydroxyandrost-4-ene-3,17-dione metabolism in breast cancer patients using high-performance liquid chromatography-mass spectrometry

1 reference

12 December 2020

Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report

1 reference

12 December 2020

Serum kinetics of the anti-cancer agent 4-hydroxyandrostenedione in the rat

1 reference

12 December 2020

Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo

1 reference

12 December 2020

The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients

1 reference

12 December 2020

Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment

1 reference

12 December 2020

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route

1 reference

12 December 2020

4-hydroxyandrostenedione--further clinical and extended endocrine observations

1 reference

12 December 2020

Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer

1 reference

12 December 2020

4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00682742

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7949207%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

1 reference